Health Care • Biotechnology: Pharmaceutical Preparations
$1.88 ▼ -0.06
(-3.09%)
MKT CAP: $59.1M • VOL: 50.6K
52W L $2 52W H $3
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
XBIT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$55.7M | -$42.5M | -$37.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$45.5M | -$38.5M | -$24.6M |
| EBITDA (Normalized) | -$55.5M | -$41.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$39.9M | -$31.0M | -$18.7M |
| Capital Expenditures (CapEx) | $289.0K | $1.3M | — |
| Free Cash Flow (FCF) | -$40.2M | -$32.3M | -$18.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $125.6M | $172.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $140.3M | $182.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XBIT.